Key clinical point : The incidence of ramucirumab-induced infusion-related reaction (IRR) was low in patients with advanced colorectal cancer (CRC) who did not receive antihistamine premedication. Moreover, not using antihistamine premedication can reduce medical costs.
Major finding: Overall, IRR was reported in 2 patients (1.4%), both of whom received antihistamine and steroids before the ramucirumab infusion. IRRs were not observed in 41 patients without antihistamine premedication, and these patients were significantly less likely to have IRR vs the previous report of cetuximab ( P < .001).
Study details: This was a retrospective, observational study including 147 patients with unresectable CRC who received ramucirumab+FOLFIRI therapy.
Disclosures: The study did not receive any funding. The authors declared no conflict of interests.
Source: Okuyama H et al. Int J Clin Oncol. 2021 Sep 2. doi: 10.1007/s10147-021-02004-9.